Comments*

 
  • Neuroscience

  • Featured Event

    Green Buildings and Health: From the Lab to the Real World

    Wednesday, December 14, 2016 | 6:00 PM - 8:30 PM
    The New York Academy of Sciences

    Researchers at Harvard T.H. Chan School of Public Health and SUNY Upstate Medical University present the results of a new study showing that employees in high-performing, green-certified buildings had higher cognitive function test scores than those in similarly high-performing buildings that were not green certified, even after controlling for other potential explanatory factors.

  • Events 

    Monday, March 13, 2017 | 8:30 AM - 6:00 PM

    Targeting Tau in Alzheimer's Disease and Related Disorders

    Speakers: Michael G. Agadjanyan (The Institute for Molecular Medicine), Bernardino Ghetti, (Indiana University School of Medicine), Andreas Muhs (AC Immune SA), Michal Novák (AXON Neuroscience SE), Einar M. Sigurdsson (NYU School of Medicine), Henrik Zetterberg (University of Gothenburg, Sweden), and Khalid Iqbal (New York State Institute for Basic Research)

    This event will cover the translational potential of immunotherapy for tauopathies, reviewing the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic approach.

    Tuesday, March 21, 2017 | 12:00 PM - 5:00 PM

    Exosomes in the CNS

    Speakers: Tsuneya Ikezu (Boston University School of Medicine), David Issadore (University of Pennsylvania), Xandra Breakefield (Massachusetts General Hospital), Efrat Levy (NYU School of Medicine), Robert A. Rissman (University of California San Diego, School of Medicine), and Andrew West (The University of Alabama at Birmingham)

    In this symposium we will explore the contribution of extracellular vesicles to pathological processes underling neurodegenerative disorders, and the appeal of exosomes as biomarkers and targets for the development of novel therapeutics.

    Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM

    Gene Therapy for Rare Diseases

    Speakers: Brian Kaspar (Nationwide Children's Hospital), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida, Powell Gene Therapy Center), Maria Escolar (Children's Hospital of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and David Pearce (Sanford Research)

    Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in field, and identify ongoing obstacles on the path to wider use of this approach.

    May 15 - 17, 2017

    13th International Conference on Myasthenia Gravis and Related Disorders

    Keynote Speaker: Vijay K. Kuchroo (Harvard Institutes of Medicine)

    Learn about most recent advances in basic, translational, and clinical research on the rare, acquired disorder, Myasthenia Gravis, as well as implications of this research on a range of related autoimmune and neuromuscular diseases.

  • Past Events

    Tuesday, December 6, 2016 | 9:00 AM - 5:00 PM

    Alzheimer's Disease as a Neurovascular Inflammatory Disorder

    Speakers: Katerina Akassoglou (University of California, San Francisco), Robert Dempsey (University of Wisconsin), Paula Grammas (University of Rhode Island), Steven Greenberg (Massachusetts General Hospital and Harvard Medical School), Jaime Grutzendler (Yale University), Costantino Iadecola (Weill Cornell Medicine), Jeffrey Iliff (Oregon Health & Science University), Berislav Zlokovic (Keck School of Medicine of USC), Heather Snyder (Alzheimer's Association), Zorina Galis (NIH)

    This symposium will highlight basic research and clinical science elucidating the mechanisms underlying the contribution of inflammatory pathways to vascular cognitive impairment and dementia (VCID).

    Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM

    Emerging Paradigms in Drug Discovery & Chemical Biology

    Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)

    Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.

    Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM

    MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications

    Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
    Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)

    miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.

    Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM

    Multiple Sclerosis: Diagnostic and Treatment Frontiers

    Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)

    Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.

  • Publications 

    Annals

    Special Issue: Annals Reports

    Edited by Annals of the New York Academy of Sciences editorial staff.

    This diverse collection of papers discusses topics ranging from a paleobiologic study of the emergence of the diaphragm to changes in gait patterns after acute brain injury.

    eBriefing

    Surgery and Cognition: Delirium, Cognitive Decline, and Opportunities to Protect the Brain

    Featuring: Sharon Inouye (Harvard Medical School)

    Surgery helps millions of Americans overcome illness to live longer, healthier lives. Yet surgery can lead to delirium, cognitive decline, and perhaps even a higher long-term risk of dementia for many patients, a risk that is poorly understood and often under-recognized in the clinic. With numerous factors—including age—contributing to each patient's level of risk, what are the challenges and opportunities to create biomarkers and therapeutics for those who are most vulnerable?

    Annals

    Special Issue: From Knowledge to Wisdom: Science and the Good Life

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals issue presents papers from a three-part series, in collaboration with the Nour Foundation, on the science of happiness, morality, and wisdom.

    Volume 1384

    Annals

    Special Issue: Countermeasures Against Chemical Threats II

    Edited by Jeffrey D. Laskin (Rutgers University School of Public Health)

    Discussions of various countermeasures to chemical threats.